JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Cohort Profile: VZNKUL-NMIBC Quality Indicators Program: A Flemish Prospective Cohort to Evaluate the Quality Indicators in the Treatment of Non-Muscle-Invasive Bladder Cancer

  • 0Department of Urology, University Hospitals Leuven, 3000 Leuven, Belgium.
Cancers +

|

November 9, 2024

|

November 9, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

This study analyzed bladder cancer treatment data from Flemish hospitals, finding that quality indicators improve adherence to guidelines. The registry will continue monitoring care to enhance patient outcomes.

Area Of Science

  • Urology
  • Oncology
  • Public Health

Background

  • Bladder cancer (BC) is a complex disease with variable outcomes.
  • Non-muscle-invasive bladder cancer (NMIBC) management relies on risk stratification and quality indicators (QCIs).
  • Previous QCI benefits were debated, but recent registry data show their value in standardizing care.

Purpose Of The Study

  • To describe demographic, clinical, and treatment data of NMIBC patients in a Flemish registry.
  • To assess adherence to European Association of Urology (EAU) Guidelines.
  • To benchmark current NMIBC care in Flemish hospitals.

Main Methods

  • Prospective cohort study of patients in the Vlaams Ziekenhuisnetwerk-KU Leuven (VZNKUL)-NMIBC Quality Indicators Program Registry.
  • Data collected from June 2013 to December 2020, including 4744 transurethral resections of bladder tumors (TURBTs).
  • Analysis of patient characteristics, tumor data, treatments (e.g., BCG, intravesical chemotherapy), oncological outcomes, and survival rates.

Main Results

  • Registry included 2237 patients; 60.4% had NMIBC, 9.3% had muscle-invasive BC (MIBC).
  • Adherence to guidelines varied; e.g., 60.7% of high-risk patients received adequate BCG induction.
  • Five-year survival rates for NMIBC patients: recurrence-free 53%, progression-free 91.6%, cancer-specific 95.6%.

Conclusions

  • The VZNKUL-NMIBC QCI program provides valuable data for monitoring and improving bladder cancer care.
  • Real-world data from this registry can inform clinical practice, guideline adherence, and future research.
  • Continued data collection is essential for benchmarking and enhancing patient outcomes in bladder cancer treatment.

Keywords: